Avalon Develop Funding Technology 
Xconomy
SEPTEMBER 27, 2016
[ Note: The headline has been corrected to better describe the company’s type of funding. Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. 9/27/16, 2:09 p.m. Bregua Corp.,
socalTECH
DECEMBER 6, 2012
San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from Avalon Ventures. Avelas is developing technology for visualizing cancerous lymph nodes in breast cancer patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
socalTECH
JANUARY 9, 2014
San Diego-based Avelas Biosciences announced today that it has raised $6.85M in a Series B funding round, for the company''s technology for illuminating cancer cells. The company said the funding came from Avalon Ventures, and also included Torrey Pines Investment, WuXi AppTec, and an additional, un-named investor.
socalTECH
JULY 20, 2016
San Diego-based Synthorx , a developer of protein therapeutics technology, said it has raised $10M in a Series B financing this morning. The funding was led by RA Capital Management, and also included Avalon Ventures and Correlation Ventures. RA Capital Management's Andrew Levin joins the company's board with the funding.
socalTECH
SEPTEMBER 10, 2014
San Diego-based Avelas Biosciences , which is developing cell penetrating peptides to light up cancerous tissue in patients during surgery, has raised $7.4M in a Series B funding. The second tranche of the company''s Series B came from investors Avalon Ventures, Torrey Pines Investment and WuXi PharmaTech Investments.
socalTECH
JULY 22, 2016
San Diego-based AristaMD , which is developing software tools to help coordinate referrals by physicians to specialists, has raised $11M in a Series A funding round. The funding was led by Avalon Ventures, and also included Correlation Ventures. READ MORE>>.
socalTECH
DECEMBER 4, 2015
The funding was led by Avalon Ventures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. The startup said it is developing novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types. READ MORE>>.
Expert insights. Personalized for you.
40 
Let's personalize your content